RFA-TS-25-036: Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
Closed
This grant is closed. A newer notice from the same program is forecast: Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS) (RFA-TS-27-018). Status: Expected deadline February 1, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2024.
Centers for Disease Control and Prevention - ERA offered grants of up to $500,000 to any type of organization. It expected to make about 8 awards worth $7.5 million in total. Applications closed on November 4, 2024.
From the official notice on Grants.gov, last changed October 9, 2024. Checked November 7, 2026.
- Award ceiling$500,000
- Total funding$7.5 million
- Expected awards8
- Cost sharingNot required
- Funding typeCooperative Agreement
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-TS-27-018 | July 8, 2026 | Expected deadline February 1, 2027 | Forecast |
| RFA-TS-26-165 | May 11, 2026 | Closed June 10, 2026 | Closed |
| RFA-TS-24-010 | August 1, 2023 | Closed December 19, 2023 | Closed |
| RFA-TS-23-001 | September 30, 2022 | Closed January 5, 2023 | Closed |
| RFA-TS-22-001 | February 14, 2022 | Closed April 22, 2022 | Closed |
| RFA-TS-21-001 | January 8, 2021 | Closed March 29, 2021 | Closed |
Key dates
| Posted | August 1, 2024 |
|---|---|
| Deadline | November 4, 2024 |
| Archived by Grants.gov | March 9, 2025 |
Who can apply
This opportunity was open to any type of organization.
All 14 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
See Section III. Eligibility Information.
Is this a realistic fit?
- Past Innovations in Applied Public Health Research awards averaged $557,604; this notice allows up to $500,000 per award.
- No cost sharing or match is required.
What the grant funds
The Centers for Disease Control/Agency for Toxic Substances and Disease Registry (CDC/ATSDR) is seeking investigator-initiated research that will identify and evaluate potential risk factors contributing to Amyotrophic Lateral Sclerosis (ALS), with preferred focus on research proposals that will examine factors related to military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents. Research proposals on preferred topics can be funded under one of three funding options, Funding Option A, Funding Option B, or Funding Option C. Funding Option A is intended to support ALS risk factor research investigations that have an existing, well substantiated evidence base and would benefit from strengthened rigorous evaluation. Funding Option B is intended to support novel ALS risk factor research investigations that may or may not have an existing evidence base, may be supported by limited and insufficient preliminary research, and are exploratory and developmental in nature. Funding Option C is intended to support research and better understanding of ALS risk including prevalence and incidence in communities such as racial and ethnic minority populations (e.g., Black or African American persons, Hispanic or Latino persons, Asian persons) and military veterans.
Who has won Innovations in Applied Public Health Research grants before
From fiscal 2021 to 2025, Innovations in Applied Public Health Research (93.061) awarded $3.9 million across 7 grant awards, an average of $557,604 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| President and Fellows of Harvard College | Massachusetts | 2 | $2.0 million |
| Firebird Biomolecular Sciences LLC | Florida | 1 | $972,101 |
| Regents of the University of Michigan | Michigan | 1 | $500,000 |
| Als Therapy Development FND | Massachusetts | 1 | $480,595 |
| Northwestern University | Illinois | 1 | $299,999 |
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-TS-27-018, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-TS-25-036 still open?
No. It closed on November 4, 2024. A newer notice is forecast: RFA-TS-27-018, expected deadline February 1, 2027.
Who can apply for Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)?
Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)?
Closed November 4, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each. About $7.5 million in total across about 8 awards.
Who has won Innovations in Applied Public Health Research grants before?
The largest recipients over five fiscal years were President and Fellows of Harvard College, Firebird Biomolecular Sciences LLC, Regents of the University of Michigan. The program made 7 awards worth $3.9 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)